Signet, Bionpharma and GMS Form Pharma Nobis to Acquire Fagron's U.S. Contract Manufacturing Business
February 4, 2022
An investor consortium led by Signet Healthcare Partners with Bionpharma, Inc. and GMS Capital Partners formed Pharma Nobis, LLC to acquire Fagron's U.S. contract manufacturing business and manufacturing facility in Texarkana, Texas. Fagron will retain a 20% interest in the new company; Todd Daviau was named CEO and the investors said they will seek to grow the contract manufacturing and private-label capabilities for consumer healthcare and retail customers.
- Buyers
- Signet Healthcare Partners, Bionpharma, Inc., GMS Capital Partners LLC, Pharma Nobis, LLC
- Targets
- Fagron's U.S. contract manufacturing business and manufacturing facility (Texarkana, Texas)
- Sellers
- Fagron
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business
July 23, 2020
Pharmaceuticals
LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.
-
Siegfried Holding AG to Acquire Noramco, Extractas Biosciences and Purisys from SK Capital Partners
January 27, 2026
Healthcare Services
Affiliates of funds advised by SK Capital Partners have entered into an agreement to sell Noramco, Extractas Biosciences, and Purisys of the Noramco Group to Siegfried Holding AG. The deal is subject to customary closing conditions and regulatory approvals, with SK Capital retaining ownership of Halo Pharmaceuticals after closing.
-
Bora Pharmaceuticals Acquires Upsher-Smith Laboratories
August 5, 2025
Pharmaceuticals
Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.
-
AmerisourceBergen Acquires PharmaLex for €1.28 Billion
December 31, 2022
Healthcare Services
AmerisourceBergen Corporation signed a definitive agreement to acquire PharmaLex Holding GmbH for €1.28 billion in cash. The deal is intended to expand AmerisourceBergen’s global biopharma services platform by adding PharmaLex’s tech-enabled, regulatory-focused life sciences expertise.
-
Signet Healthcare Partners Provides Growth Equity to Ascendia Pharmaceuticals
April 8, 2021
Pharmaceuticals
Signet Healthcare Partners, a New York-based growth equity firm, has made a growth equity investment in Ascendia Pharmaceuticals, a North Brunswick, New Jersey-based specialty CDMO. The proceeds will fund Ascendia's facility expansion and increased manufacturing capacity; Signet principals James Gale and Dr. Theron Odlaug will join Ascendia's board.
-
Fagron Acquires Purifarma in Brazil
January 6, 2026
Pharmaceuticals
Fagron has completed the acquisition of Purifarma, a large-scale pharmaceutical essentials business in Brazil, for an enterprise value of approximately R$250 million. The deal strengthens Fagron's scale and procurement position in Latin America and supports the Group's buy-and-build strategy to expand its pharmaceutical compounding and essentials platform.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.